Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKCA NASDAQ:ARVN NASDAQ:FTSV NASDAQ:INSM NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/AARVNArvinas$7.64-1.3%$7.50$5.90▼$29.61$568.25M2.381.28 million shs1.51 million shsFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/AINSMInsmed$144.75+1.1%$121.29$60.40▼$149.08$30.26B0.972.05 million shs1.45 million shsPCRXPacira BioSciences$26.51-1.3%$24.45$13.42▼$27.64$1.21B0.42591,998 shs642,423 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%ARVNArvinas-1.29%-4.50%+7.76%+2.28%-69.62%FTSVForty Seven0.00%0.00%0.00%0.00%0.00%INSMInsmed+1.12%-1.66%+13.26%+45.54%+97.66%PCRXPacira BioSciences-1.30%+0.80%+6.98%+9.77%+96.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/AARVNArvinas$7.64-1.3%$7.50$5.90▼$29.61$568.25M2.381.28 million shs1.51 million shsFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/AINSMInsmed$144.75+1.1%$121.29$60.40▼$149.08$30.26B0.972.05 million shs1.45 million shsPCRXPacira BioSciences$26.51-1.3%$24.45$13.42▼$27.64$1.21B0.42591,998 shs642,423 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%ARVNArvinas-1.29%-4.50%+7.76%+2.28%-69.62%FTSVForty Seven0.00%0.00%0.00%0.00%0.00%INSMInsmed+1.12%-1.66%+13.26%+45.54%+97.66%PCRXPacira BioSciences-1.30%+0.80%+6.98%+9.77%+96.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKCAAkcea Therapeutics 0.00N/AN/AN/AARVNArvinas 2.55Moderate Buy$19.76158.68% UpsideFTSVForty Seven 0.00N/AN/AN/AINSMInsmed 2.94Moderate Buy$139.86-3.38% DownsidePCRXPacira BioSciences 2.71Moderate Buy$30.8316.31% UpsideCurrent Analyst Ratings BreakdownLatest INSM, AKCA, FTSV, PCRX, and ARVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025INSMInsmedGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$125.00 ➝ $172.009/3/2025INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$140.00 ➝ $171.008/21/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$126.00 ➝ $144.008/20/2025INSMInsmedJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$111.00 ➝ $135.008/20/2025INSMInsmedWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform8/14/2025INSMInsmedTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$126.00 ➝ $139.008/14/2025INSMInsmedStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$121.00 ➝ $145.008/14/2025PCRXPacira BioSciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/13/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$114.00 ➝ $142.008/13/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$126.008/13/2025INSMInsmedJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$129.00 ➝ $148.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKCAAkcea Therapeutics$488.54M3.78$0.51 per share35.54$5.78 per share3.14ARVNArvinas$263.40M2.13N/AN/A$8.17 per share0.94FTSVForty Seven$15.68M293.33N/AN/A$7.52 per share12.70INSMInsmed$363.71M84.13N/AN/A$1.60 per share90.47PCRXPacira BioSciences$700.97M1.70$4.26 per share6.22$16.86 per share1.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKCAAkcea Therapeutics$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/AARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)FTSVForty Seven-$87.62M-$2.34N/AN/AN/AN/A-50.38%-44.35%N/AINSMInsmed-$913.77M-$5.71N/AN/AN/A-259.82%-195.37%-49.49%10/30/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.78N/A10.32N/A-18.08%13.29%6.61%11/5/2025 (Estimated)Latest INSM, AKCA, FTSV, PCRX, and ARVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025INSMInsmed-$1.30-$1.70-$0.40-$1.70$104.06 million$107.42 million8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/5/2025Q2 2025PCRXPacira BioSciences$0.73$0.74+$0.01-$0.11$183.11 million$181.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKCAAkcea TherapeuticsN/A12.1711.78ARVNArvinasN/A5.645.64FTSVForty SevenN/A14.8114.81INSMInsmed0.456.686.33PCRXPacira BioSciences0.502.381.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKCAAkcea Therapeutics19.27%ARVNArvinas95.19%FTSVForty Seven71.77%INSMInsmedN/APCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipAKCAAkcea Therapeutics1.50%ARVNArvinas4.73%FTSVForty Seven37.40%INSMInsmed3.00%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKCAAkcea Therapeutics248101.60 millionN/AOptionableARVNArvinas42073.42 million69.95 millionOptionableFTSVForty Seven5748.16 millionN/ANot OptionableINSMInsmed1,271211.38 million205.03 millionOptionablePCRXPacira BioSciences72044.93 million42.06 millionOptionableINSM, AKCA, FTSV, PCRX, and ARVN HeadlinesRecent News About These CompaniesRhumbline Advisers Sells 9,754 Shares of Pacira BioSciences, Inc. $PCRX5 hours ago | marketbeat.com51,764 Shares in Pacira BioSciences, Inc. $PCRX Bought by Caxton Associates LLPSeptember 12, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Boosts Stock Position in Pacira BioSciences, Inc. $PCRXSeptember 9, 2025 | marketbeat.comPacira reports inducement grants under Nasdaq listing ruleSeptember 6, 2025 | msn.comBridgeway Capital Management LLC Buys 69,744 Shares of Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comAlyeska Investment Group L.P. Takes $32.51 Million Position in Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comRafferty Asset Management LLC Takes $251,000 Position in Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Hits New 1-Year High - Here's What HappenedSeptember 5, 2025 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comPDT Partners LLC Has $5.14 Million Stock Position in Pacira BioSciences, Inc. $PCRXSeptember 3, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 2, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Acquired by Doma Perpetual Capital Management LLCSeptember 1, 2025 | marketbeat.com9,457 Shares in Pacira BioSciences, Inc. $PCRX Acquired by FORA Capital LLCSeptember 1, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Holdings Lifted by Walleye Capital LLCAugust 30, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Bought by Wellington Management Group LLPAugust 29, 2025 | marketbeat.comQuantbot Technologies LP Purchases 24,102 Shares of Pacira BioSciences, Inc. $PCRXAugust 28, 2025 | marketbeat.comMartingale Asset Management L P Takes Position in Pacira BioSciences, Inc. $PCRXAugust 27, 2025 | marketbeat.comAmerican Century Companies Inc. Increases Holdings in Pacira BioSciences, Inc. $PCRXAugust 27, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Grows Stock Holdings in Pacira BioSciences, Inc. $PCRXAugust 26, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Bought by Invesco Ltd.August 25, 2025 | marketbeat.comNuveen LLC Makes New Investment in Pacira BioSciences, Inc. $PCRXAugust 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINSM, AKCA, FTSV, PCRX, and ARVN Company DescriptionsAkcea Therapeutics NASDAQ:AKCAAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.Arvinas NASDAQ:ARVN$7.64 -0.10 (-1.29%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$7.65 +0.01 (+0.13%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Forty Seven NASDAQ:FTSVForty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.Insmed NASDAQ:INSM$144.75 +1.61 (+1.12%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$144.08 -0.67 (-0.47%) As of 09/16/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Pacira BioSciences NASDAQ:PCRX$26.51 -0.35 (-1.30%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$26.50 -0.01 (-0.02%) As of 07:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
